Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

References

• AmbatiJAmbatiBKYooSHIanchulevSAdamisAPAge-related macular degeneration: etiology, pathogenesis, and therapeutic strategiesSurv Ophthalmol200348325729312745003
   PubMed Web of Science ®Google Scholar
• BresslerNMBresslerSBFineSLAge-related macular degenerationSurv Ophthalmol19883263754132457955
   PubMed Web of Science ®Google Scholar
• GuyerDRFineSLMaguireMGHawkinsBSOwensSLMurphyRPSubfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuityArch Ophthalmol198610457027052423062
   PubMedGoogle Scholar
• GattoBCavalliMFrom proteins to nucleic acid-based drugs: the role of biotech in anti-VEGF therapyAnticancer Agents Med Chem20066428730116842232
   PubMedGoogle Scholar
• GaudreaultJFeiDRusitJSubocPShiuVPreclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administrationInvest Ophthalmol Vis Sci200546272673315671306
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol2008145223924818222192
   PubMed Web of Science ®Google Scholar
• ChangTSBresslerNMFineJTDolanCMWardJKlesertTRImproved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trialArch Ophthalmol2007125111460146917998507
   PubMedGoogle Scholar
• BhatnagarPSpaideRFTakahashiBSRanibizumab for treatment of choroidal neovascularization secondary to age-related macular degenerationRetina200727784685017891007
   PubMed Web of Science ®Google Scholar
• BrownMMBrownGCBrownHCPeetJA value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degenerationOphthalmology2008115610391045.e517976724
   PubMed Web of Science ®Google Scholar
• AveryRLPieramiciDJRabenaMDCastellarinAANasirMAGiustMJIntravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationOphthalmology20061133363372.e516458968
   PubMed Web of Science ®Google Scholar
• RichRMRosenfeldPJPuliafitoCAShort-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degenerationRetina200626549551116770255
   PubMed Web of Science ®Google Scholar
• BashshurZFHaddadZASchakalAJaafarRFSaabMNoureddinBNIntravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective studyAm J Ophthalmol2008145224925618067876
   PubMed Web of Science ®Google Scholar
• BuysYMBevacizumab: the need for controlled studies to move forwardCan J Ophthalmol200742678918059506
   PubMed Web of Science ®Google Scholar
• SinghRPKaiserPKRole of ranibizumab in management of macular degenerationIndian J Ophthalmol200755642142517951897
   PubMedGoogle Scholar
• MelamudAStinnettSFekratSTreatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injectionsAm J Ophthalmol20081461919518455144
   PubMed Web of Science ®Google Scholar
• DevenyiRGEditorial: update on the modern management of wet age-related macular degenerationCan J Ophthalmol200641213313816767199
   PubMed Web of Science ®Google Scholar
• KleinRMKleinRBAvastin versus Lucentis: ethical issues in treatment of age-related macular degenerationRetina20072791163116518046218
   PubMed Web of Science ®Google Scholar
• StepienKRosenfeldPPuliafitoCComparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degenerationRetina20092981067107319696701
   PubMed Web of Science ®Google Scholar
• LevineJMarcusISorensonJSpaideRCooneyMFreundKBMacular hemorrhage in neovascular age-related macular degeneration after stabilization with antiangiogenic therapyRetina20092981074107919734761
   PubMed Web of Science ®Google Scholar
• KaragiannisDMitropoulosPLadasILarge subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumabOphthalmologica2009223427928219390227
   PubMed Web of Science ®Google Scholar
• BakriSJKitzmannASRetinal pigment epithelial tear after intravitreal ranibizumabAm J Ophthalmol2007143350550717317396
   PubMed Web of Science ®Google Scholar
• ScupolaACoscasGSoubraneGBalestrazziENatural history of macular subretinal hemorrhage in age-related macular degenerationOphthalmologica19992132971029885385
   PubMed Web of Science ®Google Scholar
• StifterEMichelsSPragerFIntravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhageAm J Ophthalmol2007144688689217916314
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthULaquaHSchlotzer-SchrehardUViestenzANaumannGOHistopathological changes following photodynamic therapy in human eyesArch Ophthalmol2002120683584412049594
   PubMedGoogle Scholar
• SchnurrbuschUEWeltKHornLCWiedemannPWolfSHistological findings of surgically excised choroidal neovascular membranes after photodynamic therapyBr J Ophthalmol20018591086109111520762
   PubMed Web of Science ®Google Scholar
• KaempfSJohnenSSalzAKWeinbergerAWalterPThumannGEffects of bevacizumab (Avastin) on retinal cells in organotypic cultureInvest Ophthalmol Vis Sci20084973164317118344448
   PubMed Web of Science ®Google Scholar
• BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal ranibizumab (Lucentis)Ophthalmology2007114122179218218054637
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDBeyerJCPharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbitsRetina20072791260126618046235
   PubMed Web of Science ®Google Scholar
• LadasIDKaragiannisDARouvasAAKotsolisAILiotsouAVergadosISafety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injectionsRetina200929331331819287287
   PubMed Web of Science ®Google Scholar